Navigation Links
AlphaVax Announces New CMV Advisory Board
Date:1/30/2008

RESEARCH TRIANGLE PARK, N.C., Jan. 30 /PRNewswire/ -- AlphaVax has assembled its Cytomegalovirus (CMV) Advisory Board to provide expertise and advice as the company moves its CMV vaccine candidates through clinical development. To be chaired by Dr. Robert Olmsted, AlphaVax's Vice President for Research, the Board members include:

-- Mark Schleiss, MD, Professor, Associate Head for Research and the

American Legion Chair in the Department of Pediatrics and Director,

Division of Infectious Diseases, at the University of Minnesota.

-- David Bernstein, MD, Albert Sabin Professor of Pediatrics, Director,

Infectious Diseases and Director of the Gamble Program at the

Cincinnati Children's Hospital and Medical Center.

-- Robert Pass, MD, Professor, Pediatrics and Microbiology at the

University of Alabama - Birmingham.

-- Paul D. Griffiths, MD, DSc, Professor and Head of the Centre for

Virology, Division of Infection at Royal Free and University College

Medical School in London.

AlphaVax is pleased to have these distinguished researchers and clinicians in the field of cytomegalovirus provide their perspectives on advancing an alphavirus vectored CMV vaccine. "We look forward to working with our CMV Advisory Board to help design and implement post-Phase I clinical programs for assessing the potential of our CMV vaccine candidates in transplant indications, prevention of mother-to-child transmission, and prophylactic adolescent immunization," said Dr. Olmsted.

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a novel alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. In addition to programs in influenza and cytomegalovirus, important disease targets include cance
'/>"/>

SOURCE AlphaVax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. mNEMOSCIENCE GmbH Announces Global Licensing Agreement With Aporo Biomedical
2. ADVENTRX Announces Consolidation of Clinical and Management Positions
3. Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System
4. Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast
5. BD Announces Results of Shareholder Votes at Annual Meeting
6. BioMed Realty Trust Announces Tax Treatment of 2007 Distributions
7. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
8. Sunnylife Global Announces Completion of Surgical Wing of Xiang Tan World Friendship Hospital
9. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
10. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
11. Access Pharmaceuticals Announces $2.7 Million New Equity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... Visual Assay ... and celebrate the top 100 most innovative technologies and services of the past year. ... named in the Software/Services category. The winners will be announced at the 2015 R&D ...
(Date:7/24/2015)... , July 24, 2015 Ryan & Maniskas, ... in United States District Court for the Northern District of ... or entities that purchased the common stock of Avalanche Biotechnologies, ... July 31, 2014 and June 15, 2015, inclusive (the "Class ... 8, 2015, move the Court for appointment as a lead ...
(Date:7/24/2015)... -- Champions Oncology (OTC-BB: CSBR), a company engaged in the ... the development and use of oncology drugs, today announced ... the fourth quarter and fiscal year quarter ended April ... open. The company will host a conference ... a.m. EDT (6:00 a.m. PDT). To participate in the ...
(Date:7/24/2015)... The global next generation ... billion by 2022, growing at an estimated CAGR of ... study by Grand View Research, Inc. Development of faster, ... in significant reduction in cost of sequencing one base ... rates of next generation sequencing throughout the forecast period. ...
Breaking Biology Technology:Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5
... Calif., May 1 TorreyPines Therapeutics, Inc. (Nasdaq: ... ended March 31, 2009. For the three-month ... Cash and cash equivalents totaled $6.3 million at March ... Ford as its financial advisor to assist in the evaluation ...
... Fincor (Pink Sheets: FINC) through a share ... leading company in the field of water technologies, enlarges its ... Fincor also acquired the WETTECH and Advanced Cavitation Technologies. ... several natural drugs to fight Malaria and Dengue fever and ...
... Board of Directors Also Appoints a New President and ... Perrin, Ph.D., was appointed chief executive officer and Maureen ... Institute (ALS TDI) during the annual meeting of its ... passing of Sean Scott, the Institute,s previous president, due ...
Cached Biology Technology:TorreyPines Therapeutics Reports First Quarter 2009 Financial Results 2TorreyPines Therapeutics Reports First Quarter 2009 Financial Results 3TorreyPines Therapeutics Reports First Quarter 2009 Financial Results 4Fincor (FINC) Makes a Share Transfer and Enters the Market With ACTRx a New Malaria and Dengue Fever Treatment 2ALS Therapy Development Institute, the World's Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer 2ALS Therapy Development Institute, the World's Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer 3
(Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
(Date:6/24/2015)... 2015 Research and ... the "Huawei Ascend Mate 7 Fingerprint Sensor ... offering. Huawei,s technological choice for the ... than Apple,s and Samsung,s one. The Ascend Mate ... Fingerprint Cards, a main actor in capacitive sensing ...
(Date:6/23/2015)... , June 22, 2015 ... announced the addition of the "Body-Worn Temperature ... Growth, Trends and Forecast 2014 - 2020" ... offers strategic analysis of the global body-worn temperature ... has been segmented on the basis of types, ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... issue of Genes & Development, Dr. Mary Ellen Perry ... promising target for cancer therapies. , The p53 tumor ... many anticancer strategies aim to activate p53 in order ... of p53 and therefore an attractive target to modulate ...
... physicists at the University of California, San Diego has shown ... as it passes through tiny pores. The advance brings ... in the April issue of the journal Nano Letters, describes ... of hours at a potentially low cost, by measuring the ...
... serious suicide attempts or death by suicide generally decreases ... according to a new study led by Group Health ... The American Journal of Psychiatry. The study also found ... newer antidepressant medications is less than the risk posed ...
Cached Biology News:Nanopore method could revolutionize genome sequencing 2Nanopore method could revolutionize genome sequencing 3Suicide risk does not increase when adults start using antidepressants, study finds 2
... The DNA quantitation kit is used to ... the presence of RNA or protein. With this ... which can be detected with a VersaFluor or ... range of 10 ng per ml to 5 ...
... stimulating factors for assays of mouse hematopoietic ... fetal liver. Suitable for the growth ... when added to methylcellulose at a final ... Will also support growth of mouse ...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
...
Biology Products: